# MRD-guided Treatment in NPM1mut AML Patients

> **NCT03769532** · PHASE2 · TERMINATED · sponsor: **Technische Universität Dresden** · enrollment: 26 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT03769532
- **Lead sponsor:** Technische Universität Dresden
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-21
- **Primary completion:** 2025-02-13
- **Final completion:** 2025-02-13
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Feasibility
- **Last updated:** 2025-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03769532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03769532, "MRD-guided Treatment in NPM1mut AML Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03769532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*